Cohance Lifesciences Limited

Cohance Lifesciences Limited, established in 1989 and headquartered in Hyderabad, India, is a prominent contract development and manufacturing organization (CDMO) specializing in the pharmaceutical and chemical sectors. The company develops and manufactures new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (APIs), specialty chemicals, and formulated drugs. Its product offerings include small molecule APIs, advanced intermediates, antibody drug conjugates, high-purity oligonucleotide building blocks, finished dosage forms, and specialty agrochemicals. Serving global pharmaceutical, biotechnology, and fine chemical companies, Cohance Lifesciences supports the entire drug development lifecycle from process research to late-stage clinical and commercial manufacturing. A subsidiary of Berhyanda Limited since its rebranding from Suven Pharmaceuticals Limited in May 2025, the company operates internationally, with significant markets in India, the United States, and Europe. It is recognized as one of the leading providers of high-end intermediates to innovators, contributing substantially to pharmaceutical innovation and manufacturing efficiency.